DarioHealth (NASDAQ:DRIO) reported Q2 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $8.25 million.
DarioHealth (NASDAQ:DRIO) reported Q2 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $8.25 million.